Validation in type 2 diabetes of a metabolomic signature of all-cause mortality.
Massimiliano CopettiMarco Giorgio BaroniRaffaella BuzzettiMaria Gisella CavalloEfiso CossuPaola D'AngeloSalvatore De CosmoFrida LeonettiSusanna MoranoLelio MorviducciNicola NapoliSabrina PrudenteGiuseppe PuglieseAntonio Fernando SavinoVincenzo TrischittaPublished in: Diabetes/metabolism research and reviews (2023)
The metabolomic signature of mortality in the general population is only partially effective in type 2 diabetes. Prediction markers developed and validated in the general population must be revalidated if they are to be used in patients with diabetes.